Achillion Pharmaceuticals Achillion Today Achillion People Achillion Science
   
About Us
Target Markets
Product Pipeline
News Center
Investors
Corporate Information
Financial Information
Stock Information
Shareholder Services
Contact Us
Site Map
Press Releases

Shareholder Tools
All Releases
View Summary Achillion Announces Private Placement of $50 Million
Aug 18, 2010
PDF 13.2 KB Add to Briefcase
View Summary Achillion Reports Second Quarter and Six Month Financial Results
Aug 13, 2010
PDF 15.2 KB Add to Briefcase
View Summary Achillion Pharmaceuticals Announces Nomination of NS5A Inhibitor as a Lead Clinical Candidate for Treatment of HCV
Jul 22, 2010
PDF 11.9 KB Add to Briefcase
View Summary Achillion to Present at Upcoming Conference
Jun 3, 2010
PDF 9.1 KB Add to Briefcase
View Summary Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 to Treat Hepatitis C
May 11, 2010
PDF 17.0 KB Add to Briefcase
View Summary Achillion Reports First Quarter Financial Results
May 10, 2010
PDF 13.4 KB Add to Briefcase
View Summary Achillion Presents Data From Studies of ACH-1625 in Hepatitis C at the EASL International Liver Congress
Apr 15, 2010
PDF 16.5 KB Add to Briefcase
View Summary Achillion Announces Award of NIH Grant to Study Unique Antibacterial Compound Series
Mar 18, 2010
PDF 11.2 KB Add to Briefcase
View Summary Achillion Reports 2009 Fourth Quarter and Year-End Financial Results
Mar 12, 2010
PDF 15.3 KB Add to Briefcase
View Summary Achillion to Present at Upcoming Investor Conferences
Mar 5, 2010
PDF 9.4 KB Add to Briefcase
View Summary Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and Opportunistic Infections
Feb 17, 2010
PDF 13.0 KB Add to Briefcase
View Summary Achillion to Present at 12th Annual BIO CEO and Investor Conference
Feb 8, 2010
PDF 9.1 KB Add to Briefcase
View Summary Achillion Announces Closing of Underwriters' Over-Allotment Option
Feb 2, 2010
PDF 9.9 KB Add to Briefcase
View Summary Achillion Announces License Agreement for Elvucitabine Development in China
Feb 1, 2010
PDF 14.0 KB Add to Briefcase
View Summary Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
Jan 28, 2010
PDF 13.0 KB Add to Briefcase
View Summary Achillion to Host Corporate and Clinical Update Conference Call on Monday, February 1, 2010
Jan 25, 2010
PDF 12.2 KB Add to Briefcase
View Summary Achillion Prices $21.4 Million Public Offering of Common Stock
Jan 22, 2010
PDF 11.5 KB Add to Briefcase
View Summary Achillion Announces Proposed Public Offering of Common Stock
Jan 21, 2010
PDF 11.4 KB Add to Briefcase
View Summary Achillion Announces Additional Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C
Jan 11, 2010
PDF 13.8 KB Add to Briefcase
View Summary Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
Dec 15, 2009
PDF 15.1 KB Add to Briefcase
Showing 1-20 of 89 Page: 1 2 3 ... 5  Next 20
= add release to Briefcase
Print Page
Email This
  Home  |  About Us  |  Target Markets  |  Product Pipeline  |  News Center  |  Investors  |  Contact Us  |  Site Map
  © Copyright 2007 Achillion Pharmaceuticals, Inc. All rights reserved.    Terms of Use    Last Updated (June 13, 2007)